Haywood analyst Neal Gilmer recommends Organigram Holdings, maintaining a "Buy" rating and a $3.25 price target, following its acquisition of Sanity Group GmbH. This acquisition establishes Organigram as a key player in the German and European cannabis markets, complementing its leadership in Canada. The deal is expected to significantly boost Organigram's revenue and Adjusted EBITDA in fiscal years 2026 and 2027, as Gilmer raised his forward estimates.
Institutional Shareholder Services Inc. (ISS) has recommended that Organigram Global Inc. shareholders approve the company's proposed acquisition of Sanity Group GmbH. The acquisition is seen as a strategic move to increase scale, diversification, and market presence, with Organigram maintaining a strong financial position. The deal involves an upfront payment of €113.4 million in cash and shares, with potential earn-outs based on Sanity's future performance.
Agilent (A) delivered earnings and revenue surprises of 0.00% and +1.49%, respectively, for the quarter ended October 2025. Do the numbers hold clues to what lies ahead for the stock?
